StockDuty ← Dashboard Nov 06, 2026 04:52 AM ET
SignalCorporate

IRhythm plans Zio MCT FDA filing in 2027 while raising 2026 revenue outlook to $890M-$895M

iRhythm raised 2026 revenue outlook to $890M-$895M and plans Zio MCT FDA filing in 2027.

iRhythm raised 2026 revenue outlook to $890M-$895M and plans Zio MCT FDA filing in 2027.
iRhythm raised 2026 revenue outlook to $890M-$895M and plans Zio MCT FDA filing in 2027. — impact context not separately stored; see What changed.
Sources